Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170525 | 0.90 | GRIA1 (0.49) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL2171777 | 0.81 | PDE3A (0.52) | CYP11B1CYP11B2CYP19A1CYP2C9CYP2D6 | |
| SCHEMBL12479305 | 0.76 | CYP11B1 (0.47) | CYP11B1CYP11B2CYP19A1CYP2C9CYP2D6 | |
| SCHEMBL2172288 | 0.73 | GLO1 (0.43) | CYP11B1CYP11B2CYP19A1PDE3BPDE3A | |
| SCHEMBL12479229 | 0.72 | CYP11B1 (0.48) | CYP11B1CYP11B2CYP19A1CYP2C9CYP2D6 | |
| SCHEMBL2170629 | 0.72 | DYRK1A (0.44) | CYP11B1CYP11B2CYP19A1CYP1A2NPC1 | |
| SCHEMBL2171957 | 0.72 | GLO1 (0.43) | GLO1 | |
| SCHEMBL12566143 | 0.71 | GLO1 (0.55) | GLO1ALDH1A1 | |
| SCHEMBL2171073 | 0.71 | PDE3A (0.53) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL8041159 | 0.71 | CKS1B (0.52) | GLO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348018-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| WO-2010035745-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | 杏林製薬株式会社 (JP) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE3A, PDE2A, PDE3B | CYP11B1 89/4885CYP11B2 63/4885CYP19A1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.